Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-DUX4 (SRP-1001) in adults with facioscapulohumeral muscular dystrophy type 1
2023-509748-89-00Phase 2Authorised
- Sponsor
- Sarepta Therapeutics
- Start
- Feb 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of ARO-DUX4 in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Sarepta Therapeutics. Primary endpoint: Incidence, frequency, and severity of treatment-emergent adverse events. Planned start Feb 2025; status: authorised.
02
Drugs
ARO-DUX4
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on 2023-509748-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509748-89-00.